文献速递血栓与止血

低剂量地西他滨治疗成人难治性免疫性血小板减少症的前瞻性多中心研究

A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia.
PubMed 文献 · Am J Hematol · 2019-10-17

该前瞻性多中心研究评估低剂量地西他滨治疗成人难治性免疫性血小板减少症(ITP)的疗效与安全性,45例患者接受地西他滨3.5 mg/m2静脉输注连续3天,每4周1周期共3周期。治疗结束时完全缓解8例(17.78%),部分缓解15例(33.33%),中位起效时间28天,6、12、18个月持续缓解率分别为44.44%、31.11%、20.0%,不良事件发生率28.89%,无严重不良事件。

要点

  • 中位起效时间28天,6个月持续缓解率44.44%,疗效可维持至18个月。
  • 不良事件发生率28.89%,无严重不良事件,安全性可接受。

核心结论

  • 低剂量地西他滨对成人难治性ITP可能有效且安全。

研究设计与样本

  • 前瞻性多中心研究,筛选49例,排除4例,45例成人难治性ITP患者接受低剂量地西他滨治疗。
  • 地西他滨3.5 mg/m2静脉输注连续3天,每4周1周期,共3周期。
  • 入组标准为对脾切除无应答、不能耐受或不愿接受脾切除,且基线血小板计数低于30×10^9/L或存在出血症状且需进一步ITP特异性治疗。

主要发现

  • 治疗结束时完全缓解8例(17.78%),部分缓解15例(33.33%)。
  • 中位起效时间28天(范围14-70天)。
  • 7例复发患者接受地西他滨再治疗均出现血小板应答,包括1例完全缓解和6例部分缓解。
  • 6、12、18个月持续缓解率分别为44.44%(20/45)、31.11%(14/45)、20.0%(9/45)。
  • 应答者的ITP相关症状、疲劳、心理健康、恐惧及整体生活质量显著改善。

关键数值与推荐

  • 地西他滨剂量为3.5 mg/m2静脉输注连续3天,每4周1周期,共3周期。
  • 不良事件发生于13例(28.89%)患者,无严重不良事件记录。

临床怎么用

  • 对于难治性成人ITP,尤其是对脾切除无应答、不能耐受或不愿手术者,低剂量地西他滨可作为潜在治疗选择。
  • 治疗期间需每周评估至12周,之后每4周评估,关注疗效与不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a prospective, multicenter study to evaluate the efficacy and safety of low-dose decitabine in adult patients with refractory immune thrombocytopenia. Adult patients who did not respond to, did not tolerate, or were unwilling to undergo splenectomy, with either a baseline platelet count less than 30 × 109 /L or the presence of bleeding symptoms and further need of ITP-specific treatments, were enrolled. Patients received decitabine at 3.5 mg/m2 intravenously for three consecutive days per cycle, for three cycles with a four-week interval between cycles. All patients were assessed every week during the first 12 weeks and at four-week intervals thereafter. We screened 49 patients for eligibility. Four patients were excluded and 45 received decitabine. At the end of decitabine treatment, complete response was achieved in eight patients (17.78%), and partial response was achieved in 15 patients (33.33%). The median time to initial response was 28 days (range, 14-70 days). Furthermore, seven relapsed patients received decitabine retreatment and all showed platelet response, including one complete response and six partial responses. Sustained response rates at 6, 12 and 18 months were 44.44% (20/45), 31.11% (14/45) and 20.0% (9/45), respectively. For responders, immune thrombocytopenia-related symptoms, fatigue, psychological health, fear, and overall quality of life were significantly improved. Adverse events were observed in 13 (28.89%) patients. No serious adverse events were recorded. In conclusion, low dose decitabine is potentially effective and safe in the management of adults with refractory immune thrombocytopenia. This trial is registered with clinicaltrials.gov identifier: NCT01568333.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zhou H, Qin P, Liu Q, et al. A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia. Am J Hematol. 2019. PMID: 31591739. doi:10.1002/ajh.25646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。